|Company name||Intrexon Corp|
|Live stock price||[stckqut]XON[/stckqut]|
|Confident Investor Rating||Poor|
The following company description is from Google Finance: http://www.google.com/finance?q=xon
Intrexon Corporation is engaged in the business of synthetic biology. Using the Company’s suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. In March 2014, the Company acquired Medistem, Inc. In March 2014, Intrexon Corp acquired laboratory operations in Budapest, Hungary from Codexis, Inc. In August 2014, it acquired Trans Ova Genetics, L.C.
Confident Investor comments: At this price and at this time, I do not think that a Confident Investor can confidently invest in Intrexon Corp. It is not possible to confidently invest in a company that is not currently profitable.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.